Jim Cramer Believes Novo Nordisk “Is a Hold, Not a Buy”

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer shared his thoughts on. The first caller of the episode inquired about the stock, and Cramer replied:

I kind of liked it when I spoke to them. I gotta tell you, I kind of warmed up… I was in San Francisco, and I said, you know what? I get that stock a little down more… But I love Eli Lilly and David Ricks, and what can I say? You know, as long as Eli Lilly and David Ricks are putting up those numbers and they get that pill form soon, I think that Novo is a hold, not a buy.

Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels

Novo Nordisk A/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and rare blood or endocrine disorders. The company also produces some medical devices. During the January 10 episode, a caller asked if the stock was a buy, sell, or hold. Cramer responded similarly as he said:

No, I would hold it. I met with the CEO last week. I kind of, I liked him a lot. Now, I met with Dave Ricks from Lilly, and you know, he’s my favorite, but I’m not going to go against owning some Novo. I think they’re making a turn here. I think that head start they have in the pill is very good.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.